Will Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC? – Targeted Oncology
Targeted OncologyWill Combination Therapies With Immunotherapy Become the New Standard of Care For NSCLC?Targeted OncologyAfter the accelerated FDA approval of pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontl… Continue reading
